US pharma giant Eli Lilly won the first act of the GLP-1 drug war, outpacing Novo Nordisk in sales of injectable weight-loss drugs and winning about 70 per cent of the market. But a second wave is now under way: both companies have launched their products in pill form, and this time the advantage might lie with Novo.
美国制药巨头礼来公司(Eli Lilly)在这场胰高血糖素样肽-1 (GLP-1)药物之战的第一回合中获胜，在注射类减重药物的销售上跑赢了诺和诺德(Novo Nordisk)，拿下了约70%的市场份额。但如今第二波竞争已然打响：两家公司都已推出口服制剂产品，而这一次，优势或许在诺和诺德这边。
您已阅读13%（465字），剩余87%（3249字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。